{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.1","upperLimit":"68.5","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) includes patients with tumor maintained at Stable Disease (SD), Partial Response (PR) and Complete Response (CR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.","id":"OG000","title":"Small Bowel Adenocarcinoma"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}